Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California. more
| Dec '25 | ||||||
|---|---|---|---|---|---|---|
| Total Revenue | 502.73M | [{"date":"2025-12-31","value":100,"profit":true}] | ||||
| Cost of Revenue | 426.29M | [{"date":"2025-12-31","value":100,"profit":true}] | ||||
| Gross Profit | 76.44M | [{"date":"2025-12-31","value":100,"profit":true}] | ||||
| Gross Margin | 15.20% | [{"date":"2025-12-31","value":100,"profit":true}] | ||||
| Operating Expenses | 112.52M | [{"date":"2025-12-31","value":100,"profit":true}] | ||||
| Operating Income | (36.08M) | [{"date":"2025-12-31","value":-3608300000,"profit":false}] | ||||
| Total Non-Operating Income/Expense | (35.93M) | [{"date":"2025-12-31","value":-3593000000,"profit":false}] | ||||
| Pre-Tax Income | (60.74M) | [{"date":"2025-12-31","value":-6073700000,"profit":false}] | ||||
| Income Taxes | (131.00K) | [{"date":"2025-12-31","value":-13100000,"profit":false}] | ||||
| Income After Taxes | (60.61M) | [{"date":"2025-12-31","value":-6060600000,"profit":false}] | ||||
| Income From Continuous Operations | (60.61M) | [{"date":"2025-12-31","value":-6060600000,"profit":false}] | ||||
| Income From Discontinued Operations | - | [{"date":"2025-12-31","value":"-","profit":true}] | ||||
| Net Income | (60.61M) | [{"date":"2025-12-31","value":-6060600000,"profit":false}] | ||||
| EPS (Diluted) | (0.54) | [{"date":"2025-12-31","value":-54,"profit":false}] | ||||
These ratios help you determine the liquidity of the company. Higher is better.
| STLN | |
|---|---|
| Cash Ratio | 0.43 |
| Current Ratio | 1.36 |
| Quick Ratio | 1.15 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| STLN | |
|---|---|
| ROA (LTM) | -20.36% |
| ROE (LTM) | 209.81% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| STLN | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 1.14 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.14 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| STLN | |
|---|---|
| Trailing PE | NM |
| Forward PE | 0.24 |
| P/S (TTM) | 1.05 |
| P/B | -25.52 |
| Price/FCF | 56 |
| EV/R | 1.16 |
| EV/Ebitda | NM |
The Oncology Institute, Inc. (STLN) share price today is $5.91
Yes, Indians can buy shares of The Oncology Institute, Inc. (STLN) on Vested. To buy
Yes, you can purchase fractional shares of The Oncology Institute, Inc. (STLN) via the Vested app. You can start investing in The Oncology Institute, Inc. (STLN) with a minimum investment of $1.
You can invest in shares of The Oncology Institute, Inc. (STLN) via Vested in three simple steps:
The 52-week high price of The Oncology Institute, Inc. (STLN) is $7.05. The 52-week low price of The Oncology Institute, Inc. (STLN) is $2.32.
The price-to-earnings (P/E) ratio of The Oncology Institute, Inc. (STLN) is
The price-to-book (P/B) ratio of The Oncology Institute, Inc. (STLN) is -25.52
The dividend yield of The Oncology Institute, Inc. (STLN) is 0.00%
The market capitalization of The Oncology Institute, Inc. (STLN) is $628.82M
The stock symbol (or ticker) of The Oncology Institute, Inc. is STLN
Consider the share price of The Oncology Institute, Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether The Oncology Institute, Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in The Oncology Institute, Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the The Oncology Institute, Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of The Oncology Institute, Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that The Oncology Institute, Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied
